| Filed On | Filing |
|---|---|
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 14 Sep 2026 |
Form 4: Charney Laurence N, Director
Sold 5,000 shares ($275K) |
| 10 Sep 2026 | 144 |
| 07 Aug 2026 |
Form 4: Charney Laurence N, Director
Gave 5,100 shares as a gift · Gave 950 shares as a gift |
| 05 Aug 2026 | FORM 10-Q |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million |
| 15 Jun 2026 |
Form 4: Lonial Sagar, Director
Granted 8,325 Stock Tracking Unit |
| 15 Jun 2026 |
Form 4: Hume Daniel, Director
Granted 8,325 Stock Tracking Unit |
| 15 Jun 2026 |
Form 4: Hoberman Kenneth, Director
Granted 8,325 Stock Tracking Unit |
| 15 Jun 2026 |
Form 4: Echelard Yann, Director
Granted 8,325 Stock Tracking Unit |
| 15 Jun 2026 |
Form 4: Charney Laurence N, Director
Granted 8,325 Stock Tracking Unit |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On Thursday, June 11, 2026, at 9:30 a.m. Eastern Time, by means of an online meeting platform, TG Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting. Stockholders representing 113,003,414, or 73.81%, of the 153,093,879 outst... |
| 03 Jun 2026 |
8-K: Other Events
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 |
| 27 May 2026 |
8-K: Other Events
Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only |
| 06 May 2026 | FORM 10-Q |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million |
| 30 Apr 2026 |
Proxy statement: annual meeting on June 11, 2026
CEO pay $25.6M, up 36% · say-on-pay vote |
| 29 Apr 2026 | SCHEDULE 13G |
Loading...